GSK Stock Overview
Engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
GSK plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£16.34 |
| 52 Week High | UK£18.24 |
| 52 Week Low | UK£13.71 |
| Beta | 0.31 |
| 11 Month Change | 2.67% |
| 3 Month Change | 2.09% |
| 1 Year Change | 8.21% |
| 33 Year Change | -5.86% |
| 5 Year Change | -21.82% |
| Change since IPO | -30.38% |
Recent News & Updates
Recent updates
Does GSK (LON:GSK) Have A Healthy Balance Sheet?
Sep 01
GSK (LON:GSK) Is Paying Out A Dividend Of £0.15
Aug 05GSK (LON:GSK) Will Pay A Dividend Of £0.15
May 05We Think Shareholders Are Less Likely To Approve A Large Pay Rise For GSK plc's (LON:GSK) CEO For Now
May 02These 4 Measures Indicate That GSK (LON:GSK) Is Using Debt Reasonably Well
Apr 19GSK's (LON:GSK) Solid Earnings Are Supported By Other Strong Factors
Feb 07Shareholder Returns
| GSK | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | -1.1% | -4.4% | 1.1% |
| 1Y | 8.2% | 8.4% | 5.8% |
Return vs Industry: GSK matched the UK Pharmaceuticals industry which returned 8.4% over the past year.
Return vs Market: GSK exceeded the UK Market which returned 5.8% over the past year.
Price Volatility
| GSK volatility | |
|---|---|
| GSK Average Weekly Movement | 2.4% |
| Pharmaceuticals Industry Average Movement | 6.1% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in GB Market | 9.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: GSK has not had significant price volatility in the past 3 months.
Volatility Over Time: GSK's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1715 | 70,212 | Emma Walmsley | www.gsk.com |
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines.
GSK plc Fundamentals Summary
| GSK fundamental statistics | |
|---|---|
| Market cap | UK£66.63b |
| Earnings (TTM) | UK£4.03b |
| Revenue (TTM) | UK£31.45b |
16.5x
P/E Ratio2.1x
P/S RatioIs GSK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GSK income statement (TTM) | |
|---|---|
| Revenue | UK£31.45b |
| Cost of Revenue | UK£8.56b |
| Gross Profit | UK£22.89b |
| Other Expenses | UK£18.85b |
| Earnings | UK£4.03b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.99 |
| Gross Margin | 72.78% |
| Net Profit Margin | 12.83% |
| Debt/Equity Ratio | 123.0% |
How did GSK perform over the long term?
See historical performance and comparison